AtonRa Partners Lowers Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

AtonRa Partners reduced its position in DexCom, Inc. (NASDAQ:DXCM) by 7.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 8,296 shares of the medical device company’s stock after selling 647 shares during the period. DexCom accounts for approximately 2.0% of AtonRa Partners’ portfolio, making the stock its largest holding. AtonRa Partners’ holdings in DexCom were worth $1,029,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Gilbert & Cook Inc. grew its holdings in DexCom by 8.2% during the 4th quarter. Gilbert & Cook Inc. now owns 3,431 shares of the medical device company’s stock valued at $426,000 after buying an additional 261 shares in the last quarter. Silver Oak Securities Incorporated purchased a new position in DexCom during the 4th quarter valued at about $208,000. C WorldWide Group Holding A S grew its holdings in DexCom by 3.2% during the 4th quarter. C WorldWide Group Holding A S now owns 384,000 shares of the medical device company’s stock valued at $47,651,000 after buying an additional 12,000 shares in the last quarter. Cercano Management LLC grew its holdings in DexCom by 4.5% during the 4th quarter. Cercano Management LLC now owns 213,068 shares of the medical device company’s stock valued at $26,440,000 after buying an additional 9,108 shares in the last quarter. Finally, Citizens Financial Group Inc. RI purchased a new position in shares of DexCom during the fourth quarter worth about $222,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the transaction, the executive vice president now owns 42,377 shares in the company, valued at $5,839,974.37. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the sale, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 81,007 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now directly owns 333,526 shares in the company, valued at $44,479,027.36. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

DXCM has been the subject of several recent analyst reports. UBS Group boosted their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Citigroup boosted their price objective on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a report on Tuesday, April 23rd. Raymond James boosted their price objective on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday. Finally, Canaccord Genuity Group upped their target price on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $141.67.

DexCom Trading Up 1.2 %

DXCM stock traded up $1.47 during midday trading on Monday, hitting $125.81. The company had a trading volume of 3,845,948 shares, compared to its average volume of 3,056,784. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00. The stock’s 50 day moving average price is $131.13 and its 200 day moving average price is $118.81. The stock has a market cap of $50.03 billion, a price-to-earnings ratio of 80.50, a PEG ratio of 2.11 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The firm had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. As a group, equities research analysts expect that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.